SPRB (Spruce Biosciences) Institutional Ownership: 27.76% (As of Jul. 06, 2026)


SPRB Spruce Biosciences Inc SPRB
40 GF Score
Price $51.85
GF Value $4.08
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Spruce Biosciences Institutional Ownership?

Spruce Biosciences SPRB -1.26% 40 Institutional Ownership is 27.76% as of Jul. 06, 2026. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Spruce Biosciences's institutional ownership is 27.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Spruce Biosciences's Insider Ownership is 14.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Spruce Biosciences's Float Percentage Of Total Shares Outstanding is 99.05%.

Spruce Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Spruce Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spruce Biosciences Institutional Ownership Chart

Spruce Biosciences Historical Data

The historical data trend for Spruce Biosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.02 0.62 0.63 2.70 2.75 3.69 4.68 9.34 9.32 16.31
SPRB
40GF Score
Spruce Biosciences Inc SPRB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spruce Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 27.76% mean?
Spruce Biosciences (SPRB) has a Institutional Ownership of 27.76% as of Jul. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Spruce Biosciences and its competitors.
Is Spruce Biosciences' Institutional Ownership too high?
Spruce Biosciences' current Institutional Ownership is 27.76%. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' Institutional Ownership compare to TLSA and MIST?
Spruce Biosciences' Institutional Ownership of 27.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Spruce Biosciences and its competitors. Spruce Biosciences's current Institutional Ownership is 27.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $51.85 — trading 1170.8% above its estimated fair value. The current Institutional Ownership is 27.76%. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Institutional Ownership is 27.76% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spruce Biosciences (SPRB) Overvalued in 2026?

Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued. The current stock price of $51.85 is trading 1170.8% above its estimated GF Value™ of $4.08. GuruFocus considers Spruce Biosciences to be Significantly Overvalued.

Key valuation signals for SPRB:

  • Institutional Ownership: 27.76%
  • GF Value™: $4.08 vs. price of $51.85 (1170.8% above fair value)
  • GF Score™: 40/100 with 1 warning sign

No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spruce Biosciences Business Description

Address 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score

Get the complete analysis for SPRB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.85
Price
$4.08
GF Value